FDA Approves Self-Administered Skyrizi Option for Crohn's Disease Induction

The FDA has approved a subcutaneous induction regimen for Skyrizi (risankizumab-rzaa) to treat moderately to severely active Crohn's disease in adults. This new option allows patients to self-administer the treatment via an on-body injector, providing an alternative to intravenous infusion for initiating therapy. The approval is based on Phase 3 AFFIRM trial data showing improved clinical remission and endoscopic response.